Safety of intralesional injection of lauromacrogol combined with triamcinolone for infantile hemangiomas

Abstract

The efficacy of lauromacrogol injection therapy and intralesional triamcinolone for infantile hemangiomas (IH) has been well documented recently, but with an increase in serious or rare adverse reactions. The aim of this study is to investigate the safety concerns regarding intralesional injection of lauromacrogol combined with triamcinolone for IH and to study its effect on infant growth and development. A total of 1039 IH patients who were subjected to intralesional injection of lauromacrogol combined with triamcinolone in the Plastic Surgery Department of Shandong Provincial Hospital between 1 January 2015 and 31 May 2018 were enrolled in this study. When the dose of lauromacrogol and triamcinolone was less than 3.5 and 2.0 mg/kg respectively, no serious side‐effects were observed. The adverse event rate reported was 7.7%. Among the 405 patients not subjected to propranolol before the last injection, the study included three modes of treatment response: regression (82.7%), stabilization (13.8%) and failure (3.5%). By comparing height and weight to the reference standards and also by comparisons between the same‐sex groups, our results confirmed that there was no significant effect on children's height and weight, regardless of whether the injection therapy was combined with oral propranolol at the appropriate dose and with more than 4‐week intervals. Intralesional injection of lauromacrogol combined with triamcinolone in the treatment of IH was highly safe and effective.

Aesthetic outcome of intralesional injection of lauromacrogol as a single‐agent treatment for uncomplicated infantile hemangiomas: A long‐term follow‐up study

“…The chemical composition of lauromacrogol produced in China is the same as that of polidocanol and has been approved for clinical use since 2008. A retrospective study showed that an intralesional injection of lauromacrogol combined with triamcinolone under general anesthesia was safe and effective as a treatment for IH 15 . This study retrospectively evaluated the long‐term appearance of IH treated with the intralesional stratified injection of gradient‐diluted lauromacrogol alone under surface anesthesia.…”

Successful Endoscopic Sclerotherapy Using Polidocanol for Small Bowel Hemangioma

“…Surgical treatment is generally regarded as the last resort ( 18 ). There have been dermatological reports on the usefulness and tolerability of direct injection of polidocanol for the treatment of cutaneous hemangiomas ( 19 , 20 ). Despite limited information being available on the efficacy of endoscopic sclerotherapy for small bowel lesions, our case demonstrated that the treatment successfully reduced the size of the ileal hemangioma by ＞50% in comparison to the pretreatment size ( 19 ).…”

The Safety of Intralesional Steroid Injections in Young Children and Their Effectiveness in Anastomotic Esophageal Strictures—A Meta-Analysis and Systematic Review

“…The overall rate for side effects, based on 48 studies and 3,352 patients, was 7.1% (12, 34-67, 70-72, 74-77, 79, 80, 83-87). Six studies mentioned the need for additional treatment (local or systemic) for adverse events (38,40,45,52,54,69). The aggregated mean and median follow-up lengths were 17.09 and 12 months, respectively.…”